Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
80Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $780.57M | $62.87M | $1.98 |
| 2024 | $631.45M | $69.19M | $2.14 |
| 2023 | $566.77M | $48.16M | $1.60 |
| 2022 | $463.93M | $-25.00M | $-0.74 |
| 2021 | $276.87M | $71.52M | $2.05 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $2.03 per share
Typical surprise +11.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$1.92 vs $1.72beat
- Thu, May 7$1.76 vs $1.52beat
- Thu, Feb 26$2.04 vs $2.14miss
- Thu, Nov 6$2.25 vs $1.86beat
- Thu, Aug 7$1.68 vs $1.62beat
- Thu, May 8$1.49 vs $1.43beat
Estimates and results for COLL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from COLL's reported EPS growth of -0.9% a year over 4 years.
- EPS in 5 years
- $1.90
- Implied price
- $43.59
- Return from $28.23
- 9.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $21.67 — -23.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 20 | 23 | 26 | 29 |
|---|---|---|---|---|---|
| -10.9% | -7.7% | -4.6% | -1.9% | 0.5% | 2.7% |
| -5.9% | -2.5% | 0.7% | 3.6% | 6.1% | 8.5% |
| -0.9% | 2.7% | 6.1% | 9.1% | 11.8% | 14.3% |
| 4.1% | 7.9% | 11.4% | 14.6% | 17.4% | 20.0% |
| 9.1% | 13.0% | 16.8% | 20.1% | 23.1% | 25.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newsglobenewswire.com·2d ago·Negative
Collegium Announces $50 Million Accelerated Share Repurchase Program STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company's common stock. Collegium will execute the ASR a…
View source ↗